• 1
    Armitage JO,Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. J Clin Oncol 1998; 16: 27802795.
  • 2
    Horning SJ. Follicular lymphoma: Have we made any progress? Ann Oncol 2000; 11( suppl 1): 2327.
  • 3
    Godon A,Moreau A,Talmant P,Baranger-Papot L, et al. Is t(14;18)(q32;q21) a constant finding in follicular lymphoma? An interphase FISH study on 63 patients. Leukemia 2003; 17: 255259.
  • 4
    Bohen SP,Troyanskaya OG,Alter O,Warnke R, et al. Variation in gene expression patterns in follicular lymphoma and the response to rituximab. Proc Natl Acad Sci USA 2003; 100: 19261930.
  • 5
    Coiffier B. Rituximab therapy in malignant lymphoma. Oncogene 2007; 26: 36033613.
  • 6
    Marcus R,Imrie K,Belch A,Cunningham D, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 14171423.
  • 7
    Acker B,Hoppe RT,Colby TV,Cox RS, et al. Histologic conversion in the non-Hodgkin's lymphomas. J Clin Oncol 1983; 1: 1116.
  • 8
    Bastion Y,Sebban C,Berger F,Felman P, et al. Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. J Clin Oncol 1997; 15: 15871594.
  • 9
    Horning SJ,Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 1984; 311: 14711475.
  • 10
    Lossos IS,Levy R. Higher grade transformation of follicular lymphoma: Phenotypic tumor progression associated with diverse genetic lesions. Semin Cancer Biol 2003; 13: 191202.
  • 11
    Lo Coco F,Gaidano G,Louie DC,Offit K, et al. p53 mutations are associated with histologic transformation of follicular lymphoma. Blood 1993; 82: 22892295.
  • 12
    Yano T,Jaffe ES,Longo DL,Raffeld M. MYC rearrangements in histologically progressed follicular lymphomas. Blood 1992; 80: 758767.
  • 13
    Davies AJ,Rosenwald A,Wright G,Lee A, et al. Transformation of follicular lymphoma to diffuse large B-cell lymphoma proceeds by distinct oncogenic mechanisms. Br J Haematol 2007; 136: 286293.
  • 14
    Lossos IS,Warnke R,Levy R. BCL-6 mRNA expression in higher grade transformation of follicle center lymphoma: Correlation with somatic mutations in the 5′ regulatory region of the BCL-6 gene. Leukemia 2002; 16: 18571862.
  • 15
    Elenitoba-Johnson KS,Gascoyne RD,Lim MS,Chhanabai M, et al. Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood 1998; 91: 46774685.
  • 16
    Pinyol M,Cobo F,Bea S,Jares P, et al. p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood 1998; 91: 29772984.
  • 17
    Goff LK,Neat MJ,Crawley CR,Jones L, et al. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol 2000; 111: 618625.
  • 18
    Dave SS,Wright G,Tan B,Rosenwald A, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004; 351: 21592169.
  • 19
    Glas AM,Kersten MJ,Delahaye LJ,Witteveen AT, et al. Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood 2005; 105: 301307.
  • 20
    Lossos IS,Alizadeh AA,Diehn M,Warnke R, et al. Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc Natl Acad Sci USA 2002; 99: 88868891.
  • 21
    de Vos S,Hofmann WK,Grogan TM,Krug U, et al. Gene expression profile of serial samples of transformed B-cell lymphomas. Lab Invest 2003; 83: 271285.
  • 22
    Alizadeh AA,Eisen MB,Davis RE,Ma C, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503511.
  • 23
    Hans CP,Weisenburger DD,Greiner TC,Gascoyne RD, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275282.
  • 24
    Wright G,Tan B,Rosenwald A,Hurt EH, et al. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci USA 2003; 100: 99919996.
  • 25
    Swerdlow SH,Campo E,Harris NL,Jaffe ES, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. Lyon: IARC Press; 2008.
  • 26
    Andreasson U,Ek S,Merz H,Rosenquist R, et al. B cell lymphomas express CX3CR1 a non-B cell lineage adhesion molecule. Cancer Lett 2008; 259: 138145.
  • 27
    Linderoth J,Eden P,Ehinger M,Valcich J, et al. Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 423432.
  • 28
    de Jong D,Koster A,Hagenbeek A,Raemaekers J, et al. Impact of the tumor microenvironment on prognosis in follicular lymphoma is dependent on specific treatment protocols. Haematologica 2009; 94: 7077.
  • 29
    Alvaro T,Lejeune M,Salvado MT,Lopez C, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol 2006; 24: 53505357.
  • 30
    Carreras J,Lopez-Guillermo A,Fox BC,Colomo L, et al. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood 2006; 108: 29572964.
  • 31
    Farinha P,Masoudi H,Skinnider BF,Shumansky K, et al. Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood 2005; 106: 21692174.
  • 32
    Glas AM,Knoops L,Delahaye L,Kersten MJ, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. J Clin Oncol 2007; 25: 390398.
  • 33
    Lee AM,Clear AJ,Calaminici M,Davies AJ, et al. Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol 2006; 24: 50525059.
  • 34
    de Jong D. Molecular pathogenesis of follicular lymphoma: A cross talk of genetic and immunologic factors. J Clin Oncol 2005; 23: 63586363.
  • 35
    Amen F,Horncastle D,Elderfield K,Banham AH, et al. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients. Histopathology 2007; 51: 7079.
  • 36
    Sjo LD,Poulsen CB,Hansen M,Moller MB, et al. Profiling of diffuse large B-cell lymphoma by immunohistochemistry: Identification of prognostic subgroups. Eur J Haematol 2007; 79: 501507.
  • 37
    Shipp MA,Ross KN,Tamayo P,Weng AP, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 6874.
  • 38
    Monti S,Savage KJ,Kutok JL,Feuerhake F, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 18511861.
  • 39
    Sander CA,Yano T,Clark HM,Harris C, et al. p53 mutation is associated with progression in follicular lymphomas. Blood 1993; 82: 19942004.
  • 40
    Davies AJ,Lee AM,Taylor C,Clear AJ, et al. A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma. Leukemia 2005; 19: 14591465.
  • 41
    Martinez-Climent JA,Alizadeh AA,Segraves R,Blesa D, et al. Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood 2003; 101: 31093117.
  • 42
    Hoyer KK,Pang M,Gui D,Shintaku IP, et al. An anti-apoptotic role for galectin-3 in diffuse large B-cell lymphomas. Am J Pathol 2004; 164: 893902.
  • 43
    Kim SJ,Lee SJ,Sung HJ,Choi IK, et al. Increased serum 90K and Galectin-3 expression are associated with advanced stage and a worse prognosis in diffuse large B-cell lymphomas. Acta Haematol 2008; 120: 211216.
  • 44
    Hayward DG,Clarke RB,Faragher AJ,Pillai MR, et al. The centrosomal kinase Nek2 displays elevated levels of protein expression in human breast cancer. Cancer Res 2004; 64: 73707376.
  • 45
    Hames RS,Fry AM. Alternative splice variants of the human centrosome kinase Nek2 exhibit distinct patterns of expression in mitosis. Biochem J 2002; 361: 7785.
  • 46
    Noguchi K,Fukazawa H,Murakami Y,Uehara Y. Nucleolar Nek11 is a novel target of Nek2A in G1/S-arrested cells. J Biol Chem 2004; 279: 3271632727.
  • 47
    Fry AM,Meraldi P,Nigg EA. A centrosomal function for the human Nek2 protein kinase, a member of the NIMA family of cell cycle regulators. EMBO J 1998; 17: 470481.
  • 48
    Inohara H,Raz A. Functional evidence that cell surface galectin-3 mediates homotypic cell adhesion. Cancer Res 1995; 55: 32673271.
  • 49
    Lin HM,Moon BK,Yu F,Kim HR. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000; 21: 19411945.
  • 50
    Moon BK,Lee YJ,Battle P,Jessup JM, et al. Galectin-3 protects human breast carcinoma cells against nitric oxide-induced apoptosis: Implication of galectin-3 function during metastasis. Am J Pathol 2001; 159: 10551060.
  • 51
    Yang RY,Hsu DK,Liu FT. Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA 1996; 93: 67376742.
  • 52
    Yu F,Finley RLJr,Raz A,Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002; 277: 1581915827.
  • 53
    Fukumori T,Oka N,Takenaka Y,Nangia-Makker P, et al. Galectin-3 regulates mitochondrial stability and antiapoptotic function in response to anticancer drug in prostate cancer. Cancer Res 2006; 66: 31143119.
  • 54
    Davis RE,Brown KD,Siebenlist U,Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001; 194: 18611874.
  • 55
    Lam LT,Wright G,Davis RE,Lenz G, et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-κB pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008; 111: 37013713.
  • 56
    Dumic J,Lauc G,Flogel M. Expression of galectin-3 in cells exposed to stress-roles of jun and NF-kappaB. Cell Physiol Biochem 2000; 10: 149158.